CDK9/CCNK(CDK9/cyclin K)
Sign in to save this workspaceUniProt CDK9: P50750; Cyclin K: O75909 · PDB · AlphaFold (P50750), AlphaFold (O75909) · Substrate: Pol2-CTD · Clone: full length / full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Pacritinib | 98.0% | 2.0% | 88.64 | 0.452 |
| 2 | Abemaciclib | 96.3% | 3.7% | 91.48 | 0.563 |
| 3 | Defactinib | 93.7% | 6.3% | 92.68 | 0.450 |
| 4 | Palbociclib | 62.5% | 37.5% | 98.75 | 0.673 |
| 5 | Darovasertib | 40.7% | 59.3% | 96.99 | 0.719 |
| 6 | Avapritinib | 30.9% | 69.1% | 97.73 | 0.644 |
| 7 | Midostaurin | 28.7% | 71.3% | 78.64 | 0.500 |
| 8 | Pazopanib | 26.9% | 73.1% | 97.49 | 0.672 |
| 9 | Neratinib | 21.1% | 78.9% | 93.18 | 0.597 |
| 10 | Pirtobrutinib | 17.5% | 82.5% | 99.49 | 0.656 |
| 11 | Vemurafenib | 14.1% | 85.9% | 96.49 | 0.598 |
| 12 | Gilteritinib | 13.9% | 86.1% | 88.97 | 0.506 |
| 13 | Sunitinib | 13.6% | 86.4% | 91.73 | 0.524 |
| 14 | Inavolisib | 12.0% | 88.0% | 100.00 | 0.679 |
| 15 | Ruxolitinib | 12.0% | 88.0% | 98.25 | 0.592 |
| 16 | Regorafenib | 11.8% | 88.2% | 95.99 | 0.719 |
| 17 | Tivozanib | 11.1% | 88.9% | 92.42 | 0.673 |
| 18 | Capivasertib | 10.4% | 89.6% | 96.48 | 0.644 |
| 19 | Sorafenib | 10.3% | 89.7% | 96.72 | 0.776 |
| 20 | Acalabrutinib | 10.0% | 90.0% | 99.50 | 0.670 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on CDK9/CCNK
Each point is one of the 92 approved drugs; color = inhibition % on CDK9/CCNK.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…